COVID-19 and organs damage: what do we know, coming to the fl attening of the curve?
https://doi.org/.31146/1682-8658-ecg-180-8-4-9
Abstract
The aim of this review is to summarize the world data about cardiovascular and digestive systems damage, caused by COVID-19 infection, known by June 2020. An attempt was made to suggest a pathophysiological explanation of structural and functional changes in internal organs. The main focus of the article is on the damage of the cardiovascular system, liver and small intestine, as well as on the diagnosing and optimizing the basic therapy for inflammatory bowel diseases, arterial hypertension and coronary heart disease.
About the Authors
O. V. Khlynova
Perm State Medical University named after Academician E. A. Wagner PSMU
Russian Federation
Russian Federation
Olga V. Khlynova - Head of the Department of Hospital Therapy and Cardiology PSMU, Corresponding Member of the Russian Academy of Sciences, Ph.D., Professor.
614000, Perm, st. Petropavlovskaya, 26
N. S. Karpunina
Perm State Medical University named after Academician E. A. Wagner PSMU
Russian Federation
Russian Federation
Nataliya S. Karpunina - Department of Hospital Therapy and Cardiology, PSMU, PhD, Professor.
614000, Perm, st. Petropavlovskaya, 26
L. M. Vasilets
Perm State Medical University named after Academician E. A. Wagner PSMU
Russian Federation
Russian Federation
Lubov M. Vasilets - Department of Hospital Therapy and Cardiology, PSMU, PhD, Professor.
614000, Perm, st. Petropavlovskaya, 26
References
1. Shlyakho E. V., Konradi A. O., Arutyunov G. P., et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):3801. (In Russ.) https://doi.org/10.15829/1560–4071–2020–3–3801
2. Temporary guidelines “Prevention, diagnosis and treat-ment of new coronavirus infection (COVID-19)”. Available https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_%D0%9CR_COVID-19_v6.pdf.
3. Burgueno Juan F., Reich A., Hazime H et al. Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD. Infl amm Bowel Dis; 2020, Volume 26, Number 6, 797–808. doi: 10.1093/ibd/izaa085.
4. Wong S. H., Lui R. N., Sung J. J. Covid-19 and the digestive system. J Gastroenterol Hepatol. 2020 Mar 25. doi: 10.1111 jgh.15047. [Epub ahead of print].
5. Musa Sh. Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): What do we know till now? Arab Journal of Gastroenterology, doi.org/10.1016/j.ajg.2020.03.002. [Epub ahead of print].
6. Yuan Tian, Long Rong, Weidong Nian, et al. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Th er. 2020;51:843–851.
7. I–Cheng Lee, TehIa Huo, Yi-Hsiang Huang. Gastrointestinal and Liver Manifestations in Patients with COVID-19. Journal of the Chinese Medical Association. doi:10.1097/JCMA.0000000000000319 [Epub ahead of print].
8. Ruochen Zang, Maria Florencia Gomez Castro, Broc T. McCune et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Science Immunology 13 May 2020: Vol. 5, Issue 47. doi: 10.1126/sciimmunol.abc3582.
9. Rajesh Bhayana, Avik Som, Matthew D Li et al. Abdominal Imaging Findings in COVID-19: Preliminary Observations. Radiology. doi.org/10.1148/radiol.2020201908 [Epub ahead of print].
10. Nobel Y. R., Phipps M., Zucker J. Gastrointestinal Symptoms and COVID-19: Case-Control Study from the United States, Gastroenterology. 2020. doi.org/10.1053/j.gas-tro.2020.04.017 [Epub ahead of print].
11. Musa Sh. Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): What do we know till now? Arab Journal of Gastroenterology. 2020. doi.org/10.1016/j.ajg.2020.03.002. [Epub ahead of print]
12. Ivashkin V. T., Sheptulin A. A., Zolnikova O. Yu., et al. New Coronavirus Infection (COVID-19) and Digestive System. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(3):7–13. (In Russ.) https://doi.org/10.22416/1382–4376–2020–30–3–7
13. Monteleone G., Ardizzoneb S. Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection? Journal of Crohn’s and Colitis, 2020, 1–3 doi:10.1093/ecco-jcc/jjaa061 Advance Access publication March 26, 2020.
14. Tursi A., Vetrone L. M., Papa A. Anti-TNF-α Agents in Inflammatory Bowel Disease and Course of COVID-19. Inflamm Bowel Dis. 2020. doi: 10.1093/ibd/izaa114 [Epub ahead of print].
15. Hon Chi Yip, Philip Chiu, Cesare Hassan et al. ISDE guidance statement: management of upper gastrointestinal endoscopy and surgery in COVID-19 outbreak. Diseases of the Esophagus. 2020;33:1–4. doi: 10.1093/dote/doaa029.
16. Zhang Ch., Shi L., Wang Fu-Sheng. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020 May;5(5):428–430. doi: 10.1016/S2468–1253(20)30057–1.
17. Li Jie, Fan Jian-Gao. Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease. J Clin Transl Hepatol. 2020;8(1):13–17. doi: 10.14218/JCTH.2020.00019.
18. Boeckmans J., Rodrigues R. M., Demuyser T. et al. COVID-19 and drug-induced liver injury: a problem of plenty or a petty point? Archives of Toxicology. doi. org/10.1007/s00204–020–02734–1 [Epub ahead of print].
19. Akhmerov A., Marbán E. COVID-19 and the Heart. Circulation Research. 2020. doi: 10.1161/CIRCRESAHA.120.317055 [Epub ahead of print].
20. Th e European Society for Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESCCOVID-19-Guidance. (Last update: 28 May 2020).
21. Chia Siang Kow, Syed Tabish Razi Zaidi, Syed Shahzad Hasan. Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19. American Journal of Cardiovascular Drugs. 2020. doi.org/10.1007/s40256–020–00406–0 [Epub ahead of print].
22. Mancia G., Rea F., Ludergnani M. et al. Renin–Angiotensin– Aldosterone System Blockers and the Risk of Covid-19. Th e New England Journal of Medicine. May, 2020: 1–10. doi: 10.1056/NEJMoa2006923.
23. Reynolds R. H., Adhikari S., Pulgarin C. et al. Renin– Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19. Th e New England Journal of Medicine. May, 2020: 1–8. doi: 10.1056/NEJMoa2008975.
24. Kuster M. Gabriela, Pfi ster Otmar, Burkard Th ilo. S ARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? European Heart Journal. 2020;41:1801–1803. doi:10.1093/eurheartj/ehaa235.
25. Alifano M., Alifano P., Forgez P. et al. Renin-angiotensin system at the heart of COVID-19 pandemic. Biochimie. 2020. doi.org/10.1016/j.biochi.2020.04.008 [Epub ahead of print].
26. Nicin Luka, Abplanalp Tyler Wesley, Mellentin Hannah. Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. European Heart Journal. 2020;41:1804–1806. doi:10.1093/eurheartj/ehaa311.
27. Sama E. Iziah, Ravera Alice, Santema T. Bernadet et al. Circulating plasma concentrations of angiotensin-con-verting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors. European Heart Journal. 2020;41: 810–1817. doi:10.1093/eurheartj/ehaa373.
28. Castiglione V., Chiriaco M., Emdin M. et al. Statin therapy in COVID-19 infection. European Heart Journal – Cardiovascular Pharmacotherapy. 2020. doi:10.1093/eh-jcvp/pvaa042 [Epub ahead of print].
29. Zheng Ying- Ying, Ma Tong Yi-, Zhan Ying Jin-. COVID-19 and the cardiovascular system. Nature Reviews. Cardiology. Volume 17; May 2020: 259–260.
30. Long B., Brady J. W., Koyfman A. et al. Cardiovascular com-plications in COVID-19. American Journal of Emergency Medicine, 2020. doi.org/10.1016/j.ajem.2020.04.048 [Epub ahead of print].
31. Tao Guo, Yongzhen Fan, Ming Chen et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. doi:10.1001/jamacardio.2020.1017. Published online March 27, 2020. Corrected on May 20, 2020.
32. Aksit E., Kirilmaz B., Gazi E et al. Ticagrelor Can Be an Important Agent in the Treatment of Severe COVID-19 Patients with Myocardial Infarction Balkan Med J. 2020 Jun 1;37(4):233–233. doi: 10.4274/balkanmedj.gale-nos.2020.2020.4.100. Epub 2020 Apr 24.
33. Boukhris M., Hillani A., Moroni F. et al. Cardiovascular implications of the COVID-19 pandemic: a global per-spective. Can J Cardiol. 2020 May 16 doi: 10.1016/j.cjca.2020.05.018 [Epub ahead of print].
34. Linz D., Pluymaekers N., Hendriks J. TeleCheck-AF for COVID-19: A European mHealth project to facilitate atrial fi brillation management through teleconsultation during COVID19. European Heart Journal. 2020; Volume 41, Issue 21, 1 June 2020:1954–1955. doi.org/10.1093/eurheartj/ehaa404.
35. Linschoten M., Asselbergs F. W. CAPACITY-COVID: a European Registry to determine the role of cardiovascu-lar disease in the COVID-19 pandemic. European Heart Journal; 2020. doi:10.1093/eurheartj/ehaa280.
Review
For citations:
Khlynova O.V., Karpunina N.S., Vasilets L.M. COVID-19 and organs damage: what do we know, coming to the fl attening of the curve? Experimental and Clinical Gastroenterology. 2020;(8):4-9. (In Russ.) https://doi.org/.31146/1682-8658-ecg-180-8-4-9
Views:
397
Email this article 